CMXHF.US CSL Limited

Healthcare Biotechnology USA Stocks
136.78 USD
Close of Nov 14, 2026
62.99 141.83
Market cap
USD 65.6B
P/E
-
P/B
4.44x
ROE
-17.8%
Dividend yield
2.20%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CMXHF.US undervalued?

Graham number

The Graham number of CSL Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CSL Limited fundamental analysis

No fundamental analysis for CSL Limited yet.

CSL Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, mar…

Full company profile